Solanezumab | Tested for Alzheimer’s disease | has failed in the final phase of clinical trials

Solanezumab, has failed in the final phase of clinical trials. If it had succeeded, it had the potential to be a blockbuster drug.

Mechanism of Solanezumab

Mechanism of Solanezumab

Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. The therapeutic rationale is that it may exert benefit by sequestering Aβ, shifting equilibria between different species of Aβ, and removing small soluble species of Aβ that are directly toxic to synaptic function.

Most drugs currently in clinical trials attack the formation of plaques in the brain. These plaques, made of misfolded amyloid-beta proteins or tau proteins, are thought to be the cause of Alzheimer’s.

Its failure has made many question whether that’s the right way to go after Alzheimer’s—and a small study published in March this year added support to the hypothesis that tau proteins may be the real culprit of Alzheimer’s. In July, the biotech company TauRx announced mild success with a drug that was designed to attack tau proteins. Other promising drugs in trials include azeliragon, which reduces brain inflammation (that has been linked to Alzheimer’s) and NPT088, which targets both amyloid-beta and tau proteins involved in Alzheimer’s but also alpha-synuclein protein which leads to other brain disorders, such as Parkinson’s.


Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association